2026 Clinical Breakthrough Presentation Submission

2026 Clinical Breakthrough Presentation Submission

SUBMISSION DEADLINE: Saturday, August 1, 2026
Clinical Breakthrough Presentations are designed to showcase the results of recent clinical trials or scientific breakthroughs that have major significance for the movement disorders field.

Presentations will take place in-person during Plenary Session 4205: MDS Keynote and Clinical Breakthroughs, from 08:00 – 09:30 on Wednesday, October 7, 2026.
SUBMISSION DEADLINE: Saturday, August 1, 2026

Submissions will be considered if they meet the following criteria:
- The topic must be critically important to the clinical/scientific community and/or the public.
- The proposal should provide results on major phase 2 or phase 3 clinical trials, or novel scientific research.
- The proposal must report the main results or outcomes of data or clinical trials that have not been previously presented; major results published or in press but not previously announced or presented at a clinical or scientific meeting will also be considered.
- The study and results reported should be novel (not simply an extension of previously published work) or definitively confirm or refute other critically important work.
- Accepted presenatations will focus on scientific significance, rather than product marketing.
The following types of studies are NOT appropriate for Clinical Breakthrough Presentations and will not be considered:
- case reports or small series of cases
- replication studies
- extensions of previously reported studies
- descriptions of study designs or plans with no presentation of data
- qualitative surveys
- reviews of existing treatments
- practice reviews
- rating scale validation
- research proposals
Please indicate the designated contact person for this submission. This individual will be the point of contact to receive all notifications and information regarding this submission, and will be expected to disseminate to others as needed.

Only if accepted will MDS contact the presenting individual directly.
Contact Name:

First NameLast Name
Contact Email:
example@example.com
Country:

Clinical Breakthrough Presentation
Title:
Category/Keyword:
Objective:
Background:
Method:
Results:
Acknowledgement: (Please note any relevant information to be disclosed)
To include figures, charts or images, please upload the file here.

Cancelof
Cancelof
Cancelof
If this submission is not accepted for Clinical Breakthrough Presentation, would you like to be considered for a Late-Breaking Abstract?
Late-breaking abstracts recognize novel, critically important research developments that occur during the lead-up to the International Congress. The criteria and definition can be found at https://www.mdscongress.org/Abstracts/Late-breaking.
Presenter Information

If accepted, please indicate the individual that will present and provide their general disclosure information.
Presenter Name:

First NameLast Name
Presenter Email:
example@example.com
Presenter Institution(s) / Affiliation(s):
Presenter Address:

Street Address

Street Address Line 2

CityState / Province

Postal / Zip Code
Country
Author Listing

If submitting this Clinical Breakthrough Presentation as an abstract, please include the author listing
First Author Name:

First NameLast Name
First Author Email:
First Author Country:
Co-Authors: Listing will appear in the order as it is entered below. Authors will be listed as last name, first initial. For example: John Smith will appear as "Smith, J."
Should be Empty:

2026 Clinical Breakthrough Presentation Submission

Clinical Breakthrough Presentation

Presenter Information

Author Listing